Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Courtney Frazier Swaney; Other
Eligibility: 40 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypertension, Pulmonary
Interventions: current marketed FLOLAN (epoprostenol sodium), new thermo stable formulation of epoprostenol sodium; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Miami Beach, Florida • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Hypertension
Interventions: Valsartan, Enalapril, placebo matched to enalapril, placebo matched to valsartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: TUDCA, Placebo; Drug
Lead sponsor: University of North Texas Health Science Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma
Interventions: Latanoprost, Dorzolamide, Timolol; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pulmonary Arterial Hypertension
Interventions: Ambrisentan; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: New Orleans, Louisiana • Charleston, South Carolina

Conditions: Hypertension, Hypertension,Essential
Interventions: Dehydrated Alcohol Injection, USP, Sham procedure; Drug · Procedure
Lead sponsor: Ablative Solutions, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Hypertension, Osteonecrosis, Osteonecrosis Due to Drug
Interventions: Intensive Antihypertensive Therapy, Conventional Antihypertensive Therapy, Symptom Survey, Semi-structured interview; Drug · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 10 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Charlotte, North Carolina • Memphis, Tennessee

Conditions: Hypertension, Medication Non-Adherence
Interventions: SMASH, Enhanced SC; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 59 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Glaucoma
Interventions: Voyager DSLT; Device
Lead sponsor: Ophthalmology Associates, Fort Worth; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Heart Failure, Pulmonary Hypertension
Interventions: Tadalafil, Placebo for tadalafil; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 21 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 62
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 55 more

Conditions: Age Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions: Text Message Reminder, Health Worker Visit; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Hypertension in Pregnancy
Interventions: Amlodipine besylate; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Fibrosis, Hypertension, Pulmonary
Interventions: Sildenafil Citrate, Placebo; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more

Conditions: Type 2 Diabetes Mellitus, Hypertension
Interventions: Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT); Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glaucoma, Ocular Hypertension
Interventions: Netarsudil Ophthalmic Solution (Rhopressa), Artificial Tears (AT); Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Pulmonary Arterial Hypertension
Interventions: Slow-paced respiration therapy; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 41
States / cities: Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more

Conditions: Hypertension, Menopause
Interventions: L-Citrulline, Placebo; Dietary Supplement
Lead sponsor: Texas Tech University; Other
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: American Medical Association; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Automated feedback regarding drug adherence; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma, Retinal Disease, Healthy
Interventions: KOWA OCT Bi-µ, Optovue iVue 100; Device
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost 0.01%, travoprost 0.004%, timolol 0.5%, hypromellose 0.3%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Racine, Wisconsin

Conditions: Weight Loss, Postpartum Weight Retention, Hypertension in Pregnancy, Diabetes Mellitus in Pregnancy, Preeclampsia, Recruitment
Interventions: Online Behavioral Weight Loss Program, Virtual weigh-in; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Polarization Sensitive Retinal Tomography for Glaucoma Diagnosis

Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

Targeting Endoplasmic Reticulum Stress in Human Hypertension

Circadian Rhythms of Aqueous Humor Dynamics in Humans

Crossover Study From Macitentan or Bosentan Over to Ambrisentan

Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)

Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma

Patient Centered Health Technology Medication Adherence Program for African American Hypertensives

Change in IOP Fluctuation After DSLT

Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure

Strategies for Improving Linkage-to-Care After Eye Disease Screening

Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation

Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension

Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

8 Weeks of L-CIT Supplementation and LIRET on Vascular Function in Hypertensive Postmenopausal Women

Improving Health Outcomes: Blood Pressure

Improving Adherence in Patients With Hypertension - A Novel Use of Communication Technology

Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Postpartum Weight Loss for Women at Elevated Cardiovascular Risk